Immunotherapy: an alternative promising therapeutic approach against cancers
The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeu...
Gespeichert in:
| Veröffentlicht in: | Molecular biology reports 2022-10, Vol.49 (10), p.9903-9913 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9913 |
|---|---|
| container_issue | 10 |
| container_start_page | 9903 |
| container_title | Molecular biology reports |
| container_volume | 49 |
| creator | Gupta, Sneh Lata Basu, Srijani Soni, Vijay Jaiswal, Rishi K. |
| description | The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus. |
| doi_str_mv | 10.1007/s11033-022-07525-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9244230</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2681440346</sourcerecordid><originalsourceid>FETCH-LOGICAL-c451t-15411f467cc52eb8530038cf259a3cdee04d9a61c42a67e7186fd2590bd6e2763</originalsourceid><addsrcrecordid>eNp9kU9r3DAQxUVpaTZpv0BPhl56cTKjP5bcQyCEtgks5NKehVYe7zrYsivZgXz7auvQkhxyEsz83tPMPMY-IZwjgL5IiCBECZyXoBVXpXnDNqi0KGWtzVu2AQFYSqPwhJ2mdA8AErV6z06E0qoGwzdsezsMSxjnA0U3PX4tXChcP1MMbu4eqJjiOHSpC_tiJWiZO1-4KdedPxRu77qQ5sK74CmmD-xd6_pEH5_eM_br-7ef1zfl9u7H7fXVtvRS4VyikoitrLT3itPOKAEgjG-5qp3wDRHIpnYVesldpUmjqdomN2HXVMR1Jc7Y5eo7LbuBGk9hjq63U-wGFx_t6Dr7vBO6g92PD7bmUnIB2eDLk0Ecfy-UZpu39NT3LtC4JMsrg1KCkMe_Pr9A78cln6fPVJ5Mao7CZIqvlI9jSpHaf8Mg2GNYdg3L5rDs37DsUSRWUcpw2FP8b_2K6g9mbJaz</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2718472138</pqid></control><display><type>article</type><title>Immunotherapy: an alternative promising therapeutic approach against cancers</title><source>SpringerLink Journals - AutoHoldings</source><creator>Gupta, Sneh Lata ; Basu, Srijani ; Soni, Vijay ; Jaiswal, Rishi K.</creator><creatorcontrib>Gupta, Sneh Lata ; Basu, Srijani ; Soni, Vijay ; Jaiswal, Rishi K.</creatorcontrib><description>The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus.</description><identifier>ISSN: 0301-4851</identifier><identifier>EISSN: 1573-4978</identifier><identifier>DOI: 10.1007/s11033-022-07525-8</identifier><identifier>PMID: 35759082</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animal Anatomy ; Animal Biochemistry ; Antigens ; Biomedical and Life Sciences ; Cancer ; Cancer therapies ; Cancer vaccines ; Cell therapy ; Chemotherapy ; Clinical trials ; Cytokines ; Cytotoxicity ; Drug dosages ; FDA approval ; Histology ; Immune checkpoint ; Immune system ; Immunotherapy ; Interferon ; Life Sciences ; Ligands ; Lymphocytes ; Lymphocytes T ; Malignancy ; Medical research ; Melanoma ; Metastasis ; Microenvironments ; Molecular biology ; Monoclonal antibodies ; Morphology ; Neoantigens ; Oncolysis ; Review ; Skin cancer ; Tumor necrosis factor-TNF ; Tumors ; Vaccines</subject><ispartof>Molecular biology reports, 2022-10, Vol.49 (10), p.9903-9913</ispartof><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022</rights><rights>This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply 2022.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c451t-15411f467cc52eb8530038cf259a3cdee04d9a61c42a67e7186fd2590bd6e2763</citedby><cites>FETCH-LOGICAL-c451t-15411f467cc52eb8530038cf259a3cdee04d9a61c42a67e7186fd2590bd6e2763</cites><orcidid>0000-0003-2180-318X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s11033-022-07525-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s11033-022-07525-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,780,784,885,27924,27925,41488,42557,51319</link.rule.ids></links><search><creatorcontrib>Gupta, Sneh Lata</creatorcontrib><creatorcontrib>Basu, Srijani</creatorcontrib><creatorcontrib>Soni, Vijay</creatorcontrib><creatorcontrib>Jaiswal, Rishi K.</creatorcontrib><title>Immunotherapy: an alternative promising therapeutic approach against cancers</title><title>Molecular biology reports</title><addtitle>Mol Biol Rep</addtitle><description>The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus.</description><subject>Animal Anatomy</subject><subject>Animal Biochemistry</subject><subject>Antigens</subject><subject>Biomedical and Life Sciences</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Cancer vaccines</subject><subject>Cell therapy</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cytokines</subject><subject>Cytotoxicity</subject><subject>Drug dosages</subject><subject>FDA approval</subject><subject>Histology</subject><subject>Immune checkpoint</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Interferon</subject><subject>Life Sciences</subject><subject>Ligands</subject><subject>Lymphocytes</subject><subject>Lymphocytes T</subject><subject>Malignancy</subject><subject>Medical research</subject><subject>Melanoma</subject><subject>Metastasis</subject><subject>Microenvironments</subject><subject>Molecular biology</subject><subject>Monoclonal antibodies</subject><subject>Morphology</subject><subject>Neoantigens</subject><subject>Oncolysis</subject><subject>Review</subject><subject>Skin cancer</subject><subject>Tumor necrosis factor-TNF</subject><subject>Tumors</subject><subject>Vaccines</subject><issn>0301-4851</issn><issn>1573-4978</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kU9r3DAQxUVpaTZpv0BPhl56cTKjP5bcQyCEtgks5NKehVYe7zrYsivZgXz7auvQkhxyEsz83tPMPMY-IZwjgL5IiCBECZyXoBVXpXnDNqi0KGWtzVu2AQFYSqPwhJ2mdA8AErV6z06E0qoGwzdsezsMSxjnA0U3PX4tXChcP1MMbu4eqJjiOHSpC_tiJWiZO1-4KdedPxRu77qQ5sK74CmmD-xd6_pEH5_eM_br-7ef1zfl9u7H7fXVtvRS4VyikoitrLT3itPOKAEgjG-5qp3wDRHIpnYVesldpUmjqdomN2HXVMR1Jc7Y5eo7LbuBGk9hjq63U-wGFx_t6Dr7vBO6g92PD7bmUnIB2eDLk0Ecfy-UZpu39NT3LtC4JMsrg1KCkMe_Pr9A78cln6fPVJ5Mao7CZIqvlI9jSpHaf8Mg2GNYdg3L5rDs37DsUSRWUcpw2FP8b_2K6g9mbJaz</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Gupta, Sneh Lata</creator><creator>Basu, Srijani</creator><creator>Soni, Vijay</creator><creator>Jaiswal, Rishi K.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-2180-318X</orcidid></search><sort><creationdate>20221001</creationdate><title>Immunotherapy: an alternative promising therapeutic approach against cancers</title><author>Gupta, Sneh Lata ; Basu, Srijani ; Soni, Vijay ; Jaiswal, Rishi K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c451t-15411f467cc52eb8530038cf259a3cdee04d9a61c42a67e7186fd2590bd6e2763</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Animal Anatomy</topic><topic>Animal Biochemistry</topic><topic>Antigens</topic><topic>Biomedical and Life Sciences</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Cancer vaccines</topic><topic>Cell therapy</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cytokines</topic><topic>Cytotoxicity</topic><topic>Drug dosages</topic><topic>FDA approval</topic><topic>Histology</topic><topic>Immune checkpoint</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Interferon</topic><topic>Life Sciences</topic><topic>Ligands</topic><topic>Lymphocytes</topic><topic>Lymphocytes T</topic><topic>Malignancy</topic><topic>Medical research</topic><topic>Melanoma</topic><topic>Metastasis</topic><topic>Microenvironments</topic><topic>Molecular biology</topic><topic>Monoclonal antibodies</topic><topic>Morphology</topic><topic>Neoantigens</topic><topic>Oncolysis</topic><topic>Review</topic><topic>Skin cancer</topic><topic>Tumor necrosis factor-TNF</topic><topic>Tumors</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Gupta, Sneh Lata</creatorcontrib><creatorcontrib>Basu, Srijani</creatorcontrib><creatorcontrib>Soni, Vijay</creatorcontrib><creatorcontrib>Jaiswal, Rishi K.</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Molecular biology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Gupta, Sneh Lata</au><au>Basu, Srijani</au><au>Soni, Vijay</au><au>Jaiswal, Rishi K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Immunotherapy: an alternative promising therapeutic approach against cancers</atitle><jtitle>Molecular biology reports</jtitle><stitle>Mol Biol Rep</stitle><date>2022-10-01</date><risdate>2022</risdate><volume>49</volume><issue>10</issue><spage>9903</spage><epage>9913</epage><pages>9903-9913</pages><issn>0301-4851</issn><eissn>1573-4978</eissn><abstract>The immune system interacts with cancer cells in multiple intricate ways that can shield the host against hyper-proliferation but can also contribute to malignancy. Understanding the protective roles of the immune system in its interaction with cancer cells can help device new and alternate therapeutic strategies. Many immunotherapeutic methodologies, including adaptive cancer therapy, cancer peptide vaccines, monoclonal antibodies, and immune checkpoint treatment, have transformed the traditional cancer treatment landscape. However, many questions remain unaddressed. The development of personalized combination therapy and neoantigen-based cancer vaccines would be the avant-garde approach to cancer treatment. Desirable chemotherapy should be durable, safe, and target-specific. Managing both tumor (intrinsic factors) and its microenvironment (extrinsic factors) are critical for successful immunotherapy. This review describes current approaches and their advancement related to monoclonal antibody-related clinical trials, new cytokine therapy, a checkpoint inhibitor, adoptive T cell therapy, cancer vaccine, and oncolytic virus.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>35759082</pmid><doi>10.1007/s11033-022-07525-8</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2180-318X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0301-4851 |
| ispartof | Molecular biology reports, 2022-10, Vol.49 (10), p.9903-9913 |
| issn | 0301-4851 1573-4978 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9244230 |
| source | SpringerLink Journals - AutoHoldings |
| subjects | Animal Anatomy Animal Biochemistry Antigens Biomedical and Life Sciences Cancer Cancer therapies Cancer vaccines Cell therapy Chemotherapy Clinical trials Cytokines Cytotoxicity Drug dosages FDA approval Histology Immune checkpoint Immune system Immunotherapy Interferon Life Sciences Ligands Lymphocytes Lymphocytes T Malignancy Medical research Melanoma Metastasis Microenvironments Molecular biology Monoclonal antibodies Morphology Neoantigens Oncolysis Review Skin cancer Tumor necrosis factor-TNF Tumors Vaccines |
| title | Immunotherapy: an alternative promising therapeutic approach against cancers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T13%3A10%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Immunotherapy:%20an%20alternative%20promising%20therapeutic%20approach%20against%20cancers&rft.jtitle=Molecular%20biology%20reports&rft.au=Gupta,%20Sneh%20Lata&rft.date=2022-10-01&rft.volume=49&rft.issue=10&rft.spage=9903&rft.epage=9913&rft.pages=9903-9913&rft.issn=0301-4851&rft.eissn=1573-4978&rft_id=info:doi/10.1007/s11033-022-07525-8&rft_dat=%3Cproquest_pubme%3E2681440346%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2718472138&rft_id=info:pmid/35759082&rfr_iscdi=true |